Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 307,597,088
  • Shares Outstanding, K 2,482,023
  • Annual Sales, $ 65,011 M
  • Annual Income, $ 18,254 M
  • EBIT $ 22,108 M
  • EBITDA $ 26,607 M
  • 60-Month Beta 0.28
  • Price/Sales 4.73
  • Price/Cash Flow 13.08
  • Price/Book 5.96

Options Overview Details

View History
  • Implied Volatility 26.75% (-0.49%)
  • Historical Volatility 23.13%
  • IV Percentile 20%
  • IV Rank 15.98%
  • IV High 53.48% on 04/10/25
  • IV Low 21.66% on 12/08/25
  • Expected Move (DTE 2) 1.98 (1.62%)
  • Put/Call Vol Ratio 1.03
  • Today's Volume 15,552
  • Volume Avg (30-Day) 29,467
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 564,119
  • Open Int (30-Day) 588,540
  • Expected Range 120.59 to 124.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.41
  • Number of Estimates 6
  • High Estimate 2.00
  • Low Estimate -1.63
  • Prior Year 2.22
  • Growth Rate Est. (year over year) -118.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
106.03 +15.42%
on 01/28/26
125.14 -2.21%
on 02/25/26
+14.19 (+13.12%)
since 01/23/26
3-Month
96.06 +27.40%
on 12/09/25
125.14 -2.21%
on 02/25/26
+16.71 (+15.82%)
since 11/25/25
52-Week
73.31 +66.93%
on 05/15/25
125.14 -2.21%
on 02/25/26
+30.94 (+33.85%)
since 02/25/25

Most Recent Stories

More News
Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026

DOR/ISL is the first non-INSTI, two-drug regimen to demonstrate non-inferiority and a similar safety profile at Week 48 to BIC/FTC/TAF in adults living with HIV-1 who had not previously received antiretroviral...

MRK : 122.86 (-0.86%)
How Is Merck & Co.'s Stock Performance Compared to Other Healthcare Stocks?

Despite Merck & Co.’s strong performance relative to its peers over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects

XLV : 157.85 (-0.01%)
MRK : 122.86 (-0.86%)
AMGN : 383.61 (+0.19%)
Merck to Participate in the TD Cowen 46th Annual Health Care Conference

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Caroline Litchfield, executive vice president and chief financial officer, and Dr. Dean Y. Li, executive vice...

MRK : 122.86 (-0.86%)
Merck Evolves Human Health Operating Structure to Support Portfolio Execution

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches...

MRK : 122.86 (-0.86%)
Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons

Second season results from the Phase 3 SMART trial were presented at the 9 th RSVVW Conference and will be shared with the U.S. FDA and other regulatory authorities

MRK : 122.86 (-0.86%)
Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine

Strategic collaboration brings together Mayo Clinic's extensive clinical insights, genomic data and Platform architecture with Merck's artificial intelligence (AI) and machine learning (ML) research capabilities...

MRK : 122.86 (-0.86%)
3 Mega-Cap Stocks for Long-Term Investors

3 Mega-Cap Stocks for Long-Term Investors

AAPL : 274.31 (+0.80%)
PG : 163.73 (-0.94%)
MRK : 122.86 (-0.86%)
Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium

Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival...

MRK : 122.86 (-0.86%)
KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment

KEYTRUDA and KEYTRUDA QLEX are the first and only PD-1 inhibitors approved for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma with PD-L1+ tumors ...

MRK : 122.86 (-0.86%)
5 Revealing Analyst Questions From Merck’s Q4 Earnings Call

5 Revealing Analyst Questions From Merck’s Q4 Earnings Call

MRK : 122.86 (-0.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 127.18
2nd Resistance Point 126.01
1st Resistance Point 124.97
Last Price 122.86
1st Support Level 122.76
2nd Support Level 121.59
3rd Support Level 120.55

See More

52-Week High 125.14
Last Price 122.86
Fibonacci 61.8% 105.34
Fibonacci 50% 99.22
Fibonacci 38.2% 93.11
52-Week Low 73.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar